SCHEMBL2517262

SCHEMBL2517262

CC(N)c1ccccc1S(=O)(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MYC P01106 1/20 0.42
CYP1A2 P05177 2/20 0.41
TTR P02766 1/20 0.40
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
NFKB1 P19838 1/20 0.38
PNMT P11086 1/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP12 P39900 1/20 0.38
MMP13 P45452 1/20 0.38
MMP14 P50281 1/20 0.38
MMP16 P51512 1/20 0.38
LMNA P02545 2/20 0.37
ALDH1A1 P00352 2/20 0.37
FABP3 P05413 1/20 0.37
FABP4 P15090 1/20 0.37
FABP5 Q01469 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6680955 0.83 GAA (0.46) CYP1A2CYP3A4CYP2D6NFKB1PNMT
SCHEMBL9098597 0.83 MYC (0.44) MYCCYP1A2TTRMMP1MMP2
SCHEMBL27852913 0.83 HSD11B1 (0.47) MYCCYP1A2TTRCYP3A4MMP1
SCHEMBL29353004 0.83 HSD11B1 (0.47) MYCCYP1A2TTRCYP3A4MMP1
SCHEMBL9617134 0.83 TTR (0.42) MYCCYP1A2TTRNFKB1MMP1
SCHEMBL27273870 0.83 TTR (0.42) MYCCYP1A2TTRNFKB1MMP1
SCHEMBL29617 0.83 HSD11B1 (0.47) MYCCYP1A2TTRCYP3A4MMP1
Ammonia Solution, Strong SCHEMBL340600 0.82 HSD11B1 (0.46) MYCCYP1A2TTRCYP3A4MMP1
SCHEMBL22345145 0.82 HSD11B1 (0.46) MYCCYP1A2TTRCYP3A4MMP1
SCHEMBL5692778 0.82 HSD11B1 (0.50) MYCCYP1A2CYP3A4MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8034787-B2 Enzyme-cleavable prodrug compounds MEDAREX, INC. (US) 2011-10-11 US disclosed
US-7816317-B2 Tripeptide prodrug compounds MEDAREX, INC. (US) 2010-10-19 US disclosed
US-20090110753-A1 Enzyme-cleavable prodrug compounds MEDAREX, INC. (US) 2009-04-30 US disclosed
US-20040198716-A1 Cysteine protease inhimbitors ARAD DORIT (US) 2004-10-07 US disclosed
WO-2002076939-A2 CYSTEINE PROTEASE INHIBITORS EXEGENICS INC. (US) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040198716-A1 Cysteine protease inhimbitors CTRL, PREP, CLPP MYC 3220/4885CYP1A2 2215/4885TTR 3447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.